Substantial underdiagnosis and underreporting: changes in reported HIV and AIDS cases in 31 provinces in China at the beginning of COVID-19
Xinsheng Wu A # , Zhongwen Wang A # , Bin Li A # , Weijie Zhang B # , Yuanyi Chen C , Guozhen Wu A , Juan Yang A and Huachun Zou![https://orcid.org/0000-0002-8161-7576](/media/client/orcid_16x16.png)
A
B
C
D
E
# These authors contributed equally to this paper
Handling Editor: Lei Zhang
Abstract
China implemented extensive non-pharmaceutical interventions (NPIs) to contain COVID-19.
National and provincial data on monthly reported HIV and AIDS cases from January 2017 to December 2020 were collected from the National Health Commission of the People’s Republic of China. We used interrupted time series analysis to assess whether COVID-19-related NPIs had an impact on reported HIV and AIDS cases in 31 provinces in China, and estimated underreported numbers of HIV and AIDS cases in the first month of the COVID-19 pandemic.
A total of 393,357 HIV cases and 254,735 AIDS cases were recorded in China from January 2017 to December 2020. Nationally, the number of reported HIV cases decreased by 25.1% in the first month of the NPIs period (January 2020) compared with the counterfactual (incidence rate ratio (IRR) 0.749; 95% confidence interval (CI) 0.664–0.845), whereas the number of reported AIDS cases decreased by 36.5% (IRR 0.635, 95% CI 0.543–0.741). An estimated 2208 HIV cases (95% CI 1209–3335) and 1525 AIDS cases (95% CI 927–2233) were underdiagnosed and underreported in the first month of the NPIs in China. The highest numbers of underdiagnosed and underreported HIV cases in the first month of NPIs were estimated in Sichuan (IRR 577, 95% CI 239–978), Guangdong (IRR 185, 95% CI 170–200) and Henan (IRR 170, 95% CI 77–286).
There was substantial underdiagnosis and underreporting of HIV and AIDS cases during the first month of the COVID-19 pandemic in China and certain provinces. Health departments should consider the specific barriers encountered during the pandemic, such as disrupted healthcare access and resource limitations, and implement targeted strategies to strengthen HIV surveillance and report systems.
Keywords: 31 provinces, China, COVID-19, HIV/AIDS, interrupted time series analysis, negative binominal regression models, non-pharmaceutical interventions (NPIs), underdiagnosis and underreporting.
References
1 WHO. Coronavirus (COVID-19) Dashboard. Number of COVID-19 cases reported to WHO. 2023. Available at https://covid19.who.int/
2 Del Amo J, Diaz A, Polo R. The impact of coronavirus disease 2019 on people with HIV. Curr Opin Infect Dis 2022; 35(1): 9-14.
| Crossref | Google Scholar |
3 Dorward J, Khubone T, Gate K, et al. The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis. Lancet HIV 2021; 8(3): e158-65.
| Crossref | Google Scholar | PubMed |
4 Wu X, Wu G, Ma Y, et al. The impact of COVID-19 non-pharmaceutical interventions on HIV care continuum in China: an interrupted time series analysis. Lancet Reg Health West Pac 2022; 29: 100569.
| Crossref | Google Scholar | PubMed |
5 Spinelli MA, Christopoulos KA, Moreira CV, et al. Viral suppression trajectories destabilized after coronavirus disease 2019 among US people with human immunodeficiency virus: an interrupted time series analysis. Clin Infect Dis 2024; 78(4): 991-4.
| Crossref | Google Scholar | PubMed |
6 Zhao T, Liu H, Bulloch G, Jiang Z, Cao Z, Wu Z. The influence of the COVID-19 pandemic on identifying HIV/AIDS cases in China: an interrupted time series study. Lancet Reg Health West Pac 2024; 44: 100995.
| Google Scholar | PubMed |
7 Konu YR, Dogo F, Dagnra CA, et al. Effect of the COVID-19 pandemic on HIV, malaria and tuberculosis indicators in Togo: an interrupted time series analysis. BMJ Glob Health 2024; 9(4): e013679.
| Crossref | Google Scholar |
8 Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 2017; 46(1): 348-55.
| Crossref | Google Scholar | PubMed |
9 Infectious Disease Prevention and Control. National Health Commission of the People’s Republic of China. 2023. Available at http://www.nhc.gov.cn/jkj/s2907/new_list.shtml?tdsourcetag=s_pcqq_aiomsg
10 Wu X, Wu G, Ma P, et al. Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysis. Infect Dis Poverty 2023; 12(1): 73.
| Crossref | Google Scholar | PubMed |
11 Cheng S, Zhao Y, Kaminga AC, Zhang X, Xu H. China’s fight against COVID-19: what we have done and what we should do next? Front Public Health 2022; 10: 548056.
| Crossref | Google Scholar | PubMed |
12 Mallapaty S. China’s zero-COVID strategy: what happens next? Nature 2022; 602(7895): 15-16.
| Crossref | Google Scholar | PubMed |
13 Lopez Bernal J, Soumerai S, Gasparrini A. A methodological framework for model selection in interrupted time series studies. J Clin Epidemiol 2018; 103: 82-91.
| Crossref | Google Scholar | PubMed |
14 Xiao H, Augusto O, Wagenaar BH. Reflection on modern methods: a common error in the segmented regression parameterization of interrupted time-series analyses. Int J Epidemiol 2021; 50(3): 1011-15.
| Crossref | Google Scholar | PubMed |
15 Newey W, West KD. A simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix. Econometrics 1987; 55(3): 706-8.
| Google Scholar |
16 Newey W, West KD. Automatic lag selection in covariance matrix estimation. Rev Eco Stud 1994; 61: 631-53.
| Google Scholar |
17 Geng M-J, Zhang H-Y, Yu L-J, et al. Changes in notifiable infectious disease incidence in China during the COVID-19 pandemic. Nat Commun 2021; 12(1): 6923.
| Crossref | Google Scholar | PubMed |
18 Sun Y, Zhan Y, Li H, et al. Stakeholder efforts to mitigate antiretroviral therapy interruption among people living with HIV during the COVID-19 pandemic in China: a qualitative study. J Int AIDS Soc 2021; 24(9): e25781.
| Crossref | Google Scholar | PubMed |
19 Xiao H, Dai X, Wagenaar BH, et al. The impact of the COVID-19 pandemic on health services utilization in China: time-series analyses for 2016–2020. Lancet Reg Health West Pac 2021; 9: 100122.
| Google Scholar |
20 Suen YT, Chidgey A. Disruption of HIV service provision and response in Hong Kong during COVID-19: issues of privacy and space. J Int Assoc Provid AIDS Care 2021; 20: 23259582211059588.
| Crossref | Google Scholar | PubMed |
21 Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature 2008; 455(7213): 609-11.
| Crossref | Google Scholar | PubMed |
22 Wang Y, Cochran C, Xu P, et al. Acquired immunodeficiency syndrome/human immunodeficiency virus knowledge, attitudes, and practices, and use of healthcare services among rural migrants: a cross-sectional study in China. BMC Public Health 2014; 14: 158.
| Crossref | Google Scholar | PubMed |
23 Li W, Jiang J, Su J, et al. Commercial sexual behaviors among male rural-to-urban migrants in Western China: implications for HIV prevention. Asia Pac J Public Health 2017; 29(5): 388-400.
| Crossref | Google Scholar | PubMed |
24 Sun Y, Li H, Luo G, et al. Antiretroviral treatment interruption among people living with HIV during COVID-19 outbreak in China: a nationwide cross-sectional study. J Int AIDS Soc 2020; 23(11): e25637.
| Crossref | Google Scholar | PubMed |
25 Wang H. HIV care during the coronavirus disease-2019 pandemic in Shenzhen, China. Curr Opin HIV AIDS 2020; 15(6): 341-4.
| Crossref | Google Scholar | PubMed |
26 Hoover KW, Zhu W, Gant ZC, et al. HIV services and outcomes during the COVID-19 pandemic – United States, 2019–2021. MMWR Morb Mortal Wkly Rep 2022; 71(48): 1505-10.
| Crossref | Google Scholar | PubMed |
27 Dobreva Z, Gimma A, Rohan H, et al. Characterising social contacts under COVID-19 control measures in Africa. BMC Med 2022; 20(1): 344.
| Crossref | Google Scholar | PubMed |